Navigation Links
Moffitt Cancer Center: Growing interest in prognostic test for non-small cell lung cancer
Date:4/26/2010

Tampa, FL (April 23, 2010) Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for Non Small Lung Cancer patients. Each year, more than 200,000 Americans are diagnosed with lung cancer.

The ERCC1 Analysis measures ERCC1 levels in cells to predict response to cisplatin-based chemotherapy. The correlation between ERCC1 levels and therapy response was discovered at Moffitt Cancer Center and exclusively licensed to Genzyme Corporation in November of 2007. Genzyme Genetics, a business unit of Genzyme Corporation, officially launched the ERCC1 Analysis on May 1, 2009.

Several studies1-6 have shown that evaluating the expression levels of excision repair cross-complementation group 1 (ERCC1) may help physicians identify patients that may benefit from platinum-based chemotherapy - currently considered the standard of care in advanced NSCLC. Specifically, low expression levels of ERCC1 have been related to a better response and survival benefit from adjuvant cisplatin-based chemotherapy.

"We are very pleased that many medical oncologists have begun utilizing this lung cancer test to better identify chemotherapy for non small cell lung cancer patients," said Jarett Rieger, Director of the Office of Technology Management and Licensing at Moffitt. "This test is an example of personalized medicine emanating from Moffitt Cancer Center, and as a result of our licensing partnership with Genyzme this test can now benefit lung cancer patients."

"The ERCC1 test complements our growing menu of personalized tests that predict response to treatment in NSCLC, said Celeste Chenet-Monte, Director Marketing, Oncology at Genzyme Genetics. "Other tests on our menu include EGFR and KRAS mutation analysis, ALK gene rearrangements and EGFR amplification, all of which can be used for prediction of response to targeted therapies used to treat patients with advanced NSCLC."

According to a 5-year retrospective study (n= 389) published in the New England Journal of Medicine, overall survival was significantly longer for patients with ERCC1-negative tumors who had received adjuvant cisplatin chemotherapy when compared to the control group treated by surgery alone (56 months vs 42 months, respectively). Among patients with ERCC1-positive tumors, there was no significant difference in survival between the adjuvant chemotherapy group and the control group (50 months vs 55 months respectively).


'/>"/>

Contact: Michelle Foley
Michelle.Foley@moffitt.org
813-745-1505
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related biology news :

1. Moffitt Cancer Center signs licensing agreement with Proteacel, LLC
2. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
3. A study by the MUHC and McGill University opens a new door to understanding cancer
4. ESF EURYI award winner aims to stop cancer cells reading their own DNA
5. Protein chatter linked to cancer activation
6. Newly created cancer stem cells could aid breast cancer research
7. Western diet linked to increased risk of colon cancer recurrence
8. Obesity and lack of exercise could enhance the risk of pancreatic cancer
9. Low levels of key protein may indicate pancreatic cancer risk
10. Birth records hold pancreatic cancer clue
11. Many parents at-risk for cancer disclose genetic test results to children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
Breaking Biology Technology: